- Home
- PALO vs OTLK Comparison
PALO vs OTLK Comparison
Compare PALO & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PALO | OTLK |
|---|---|---|
| Founded | N/A | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 211.0M | 249.6M |
| IPO Year | 2026 | 2016 |
Fundamental Metrics
Financial Performance| Metric | PALO | OTLK |
|---|---|---|
| Price | $9.95 | $0.96 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | 18.1K | ★ 13.7M |
| Earning Date | N/A | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,146,123.00 |
| Revenue This Year | N/A | $1,430.98 |
| Revenue Next Year | N/A | $173.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.89 | $0.16 |
| 52 Week High | $9.95 | $3.39 |
Technical Indicators
Market Signals| Indicator | PALO | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 61.50 | 38.39 |
| Support Level | $9.90 | $0.26 |
| Resistance Level | N/A | $1.83 |
| Average True Range (ATR) | 0.02 | 0.20 |
| MACD | 0.00 | -0.08 |
| Stochastic Oscillator | 100.00 | 13.84 |
Price Performance
Historical ComparisonAbout PALO Paloma Acquisition Corp I Class A Ordinary Shares
Paloma Acquisition Corp I is a blank check company incorporated as a Cayman Islands exempted company and formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.